Introduction: Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET) may offer partial or complete objective response in up to 30% of patients. To deliver treatment in a safe and effective manner, long term adverse events should be considered.
Aim(s): Our objective was to evaluate the clinical characteristics of PRRT patients who developed secondary hematologic malignancies (HM) as a long-term toxicity.
Materials and methods: Patients (pts) eligible for evaluation received PRRT for unresectable NETs between April 1997 - December 2010. Parameters including age, gender, time interval from diagnosis to hematologic malignancy, total cumulative radiolabel dose (GBq), and treatments were analyzed by descriptive statistics. Comparative analysis was performed using t- and z-tests.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Suzanne Richter
, Xenocostas A
, Sanatani M
, Davidson R
, Novak K
, Quan D
, Mujoomdar A
, Gray D
, Laidley D
, Bryanton M
, Ernst S
, Kocha W
, Reid R H
To read results and conclusion, please login ...
Further abstracts you may be interested in